NASDAQ: CLDXCelldex Therapeutics Inc Stock
$27.44-0.45 (-1.61%)
Updated Nov 29, 2024
CLDX Price
$27.44
Fair Value Price
-$4.88
Market Cap
$1.82B
52 Week Low
$22.93
52 Week High
$53.18
P/E
-10.64x
P/B
2.32x
P/S
225.88x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.98M
Earnings
-$154.08M
Gross Margin
100%
Operating Margin
-1,544.48%
Profit Margin
-1,544.5%
Debt to Equity
0.05
Operating Cash Flow
-$158M
Beta
0.83
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CLDX Overview
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CLDX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Value
C
Growth
F
Momentum
C
Sentiment
F
Safety
D
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CLDX
Ranked#314 of 340
Ranked#314 of 340
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $27.61 | A | |
| $7.72 | A | |
| $57.68 | A |
Be the first to know about important CLDX news, forecast changes, insider trades & much more!
CLDX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CLDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CLDX ($27.44) is overvalued by 661.74% relative to our estimate of its Fair Value price of -$4.88 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CLDX ($27.44) is not significantly undervalued (661.74%) relative to our estimate of its Fair Value price of -$4.88 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CLDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CLDX due diligence checks available for Premium users.
Valuation
CLDX fair value
Fair Value of CLDX stock based on Discounted Cash Flow (DCF)
Price
$27.44
Fair Value
-$4.88
Undervalued by
661.74%
CLDX ($27.44) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CLDX ($27.44) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CLDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CLDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.64x
Industry
-107.59x
Market
27.74x
CLDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.32x
Industry
5.61x
CLDX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CLDX's financial health
Profit margin
Revenue
$3.2M
Net Income
-$42.1M
Profit Margin
-1,320%
CLDX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CLDX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$823.2M
Liabilities
$37.3M
Debt to equity
0.05
CLDX's short-term assets ($778.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLDX's short-term assets ($778.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLDX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CLDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$55.3M
Investing
$47.8M
Financing
$1.2M
CLDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CLDX vs Biotech Stocks
Celldex Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.